New subsidiary will further the Company’s research into treating COVID-related heart muscle injury. A patent has been filed for a therapy to ameliorate and potentially repair myocardial damage. NEW YORK, March 16, 2021 (GLOBE NEWSWIRE) — via InvestorWire — Healthtech Solutions, Inc. (OTC: HLTT) (the “Company”), parent company of Medi-Scan, Inc., today […]
Other News
Elixir Medical Announces Commencement of INFINITY-SWEDEHEART Randomized Controlled Trial of DynamX Coronary Bioadaptor System
2,400-Patient Trial Utilizes Globally-Respected SWEDEHEART Registry Database in Randomized Study of First Metallic Device Treating Coronary Artery Disease That Adapts to Vessel Physiology MILPITAS, Calif.–(BUSINESS WIRE)–Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced commencement of the INFINITY-SWEDEHEART randomized controlled trial (RCT) of the DynamX™ Coronary Bioadaptor System, the […]
PhaseBio Reports Fourth-Quarter and Full-Year 2020 Financial Results and Recent Business Highlights
Provides overview of bentracimab development program during virtual Investor & Analyst Day, March 15, 2021, 12 – 2 pm ET Announced commercial supply agreement with BioVectra to support the development and commercialization of lead product candidate bentracimab Expanded pivotal Phase 3 REVERSE-IT trial of bentracimab into Canada and the European […]
Zora Biosciences Licenses Ceramide Technology to Quest Diagnostics for Cardiovascular Mortality Prediction Test
SECAUCUS, N.J. and HELSINKI, March 15, 2021 /PRNewswire/ — Zora Biosciences Oy, a clinical diagnostics company whose mission is to identify robust markers of disease and develop them into high-throughput, health-economic value-added clinical methods, today announced it has signed a non-exclusive license agreement with Quest Diagnostics (NYSE: DGX), the world leader in diagnostic information services, […]
Cardinal Health signs definitive agreement to sell its Cordis business to Hellman & Friedman
DUBLIN, Ohio, March 12, 2021 /PRNewswire/ — Cardinal Health (NYSE: CAH) today announced that it has signed a definitive agreement to sell its Cordis business to Hellman & Friedman (H&F) for approximately $1 billion, which includes buyer’s assumption of certain liabilities and seller’s retention of certain working capital accounts. The transaction is expected to close […]
Neovasc Announces Fourth Quarter and Fiscal Year 2020 Financial Results
VANCOUVER and MINNEAPOLIS, March 11, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), today reported financial results for the fourth quarter and fiscal year ended December 31, 2020. Fourth Quarter Highlights Generated revenue of $514,000 in the quarter and $1.96 million for the full year as Reducer […]
First Patients Enrolled in the Merit WRAPSODY AV Access Efficacy Pivotal Study
U.S. pivotal study to determine safety and effectiveness of the WRAPSODY Endovascular Stent Graft System in the treatment of dialysis outflow circuit stenosis or occlusion SOUTH JORDAN, Utah, March 11, 2021 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable medical devices […]
Paragonix Technologies, Inc. Announces Founder Lisa Anderson, Ph.D. as CEO & President
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Paragonix Technologies, Inc. announced today that Lisa Anderson, Ph.D., has been elevated to the role of CEO. Dr. Anderson succeeds William Edelman, who has served as Chairman and CEO since 2012 and recently announced his retirement. John Cammett, member of the Board for over three years, will assume the […]
Altasciences Conducts Preclinical Studies in Support of Verve Therapeutics’ Gene Editing Approach for Cardiovascular Disease
LAVAL, Quebec–(BUSINESS WIRE)–Altasciences is proud to have conducted preclinical studies for Verve Therapeutics that support the development and advancement of Verve’s gene editing approach to treating cardiovascular diseases. Altasciences’ Seattle team performed intravenous preclinical studies, including supporting analyses of pharmacodynamic markers and whole liver DNA editing, in non-human primates, that show […]
PhaseBio Pharmaceuticals and BioVectra Enter into Supply Agreement to Support Development and Commercialization of Bentracimab
MALVERN, Pa. & SAN DIEGO–(BUSINESS WIRE)–PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, and BioVectra Inc., an innovative global contract development and manufacturing organization (CDMO), today announced a commercial scale supply agreement for the production of bentracimab, PhaseBio’s […]
Recent
Nyra Medical Receives Prestigious Jon DeHaan Foundation Award for Innovation in Cardiology at EuroPCR 2026
AHN’s Allegheny General Hospital Unveils New, State-of-the-Art Cardiac Cath and Electrophysiology Labs, following Completion of $19 Million Renovation Project
egnite Expands Medical Advisory Board with Three Nationally Recognized Cardiovascular Specialists
Popular
- No commented posts yet